2. Protein Tyrosine Kinase/RTK MAPK/ERK Pathway Stem Cell/Wnt JAK/STAT Signaling PI3K/Akt/mTOR
  3. FLT3 p38 MAPK STAT PI3K Akt
  4. IMC-EB10

IMC-EB10 (LY3012218) is an anti-FLT3 monoclonal antibody. IMC-EB10 binds to FLT3 with high affinity (Kd = 158 pM) and blocks the binding of FLT3 ligand to FLT3 (IC50 ≈ 10 nM), thereby inhibiting MAPK, STAT5, and PI3K/Akt signaling in leukemia cells. IMC-EB10 can enhance the anti-leukemic effect of Methotrexate (HY-14519) and inhibit leukemias expressing wild-type or ITD-mutated FLT3 receptors. IMC-EB10 prolongs the survival of acute lymphoblastic leukemia (ALL) cells and primary leukemia samples and reduces engraftment in non-obese diabetic/severe combined immunodeficiency patients. IMC-EB10 is indicated for leukemia research.

For research use only. We do not sell to patients.

IMC-EB10

IMC-EB10 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

IMC-EB10 Related Antibodies

Top Publications Citing Use of Products

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

IMC-EB10 (LY3012218) is an anti-FLT3 monoclonal antibody. IMC-EB10 binds to FLT3 with high affinity (Kd = 158 pM) and blocks the binding of FLT3 ligand to FLT3 (IC50 ≈ 10 nM), thereby inhibiting MAPK, STAT5, and PI3K/Akt signaling in leukemia cells. IMC-EB10 can enhance the anti-leukemic effect of Methotrexate (HY-14519) and inhibit leukemias expressing wild-type or ITD-mutated FLT3 receptors. IMC-EB10 prolongs the survival of acute lymphoblastic leukemia (ALL) cells and primary leukemia samples and reduces engraftment in non-obese diabetic/severe combined immunodeficiency patients. IMC-EB10 is indicated for leukemia research[1][2][3][4].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target[1][4]

STAT5

 

In Vitro

IMC-EB10 (10 μg/mL, 1 h) reduces FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK in Hb1119 and SEM-K2 cells, but activates them in REH and RS411 cells[1].
IMC-EB10 (10 μg/mL, 1 h) activates FLT3 and downstream Akt in ALLs[1].
IMC-EB10 (0.4-200 nM, 1 h) inhibits FLT3-Fc-induced phosphorylation of wild-type FLT3 and ligand-independent constitutive phosphorylation of ITD-mutant FLT3 in EOL-1, EM3, BaF3-ITD and MV4;11 cells[4].
IMC-EB10 (0.4-200 nM, 1 h) inhibits FLT3-Fc-induced phosphorylation of MAPK, AKT and Stat5 in EOL-1, EM3, BaF3-ITD and MV4;11 cells[4].
IMC-EB10 (1.5-100 nM, 1 h) inhibits proliferation of FLT3-Fc-induced proliferation of EOL-1 and BaF3-ITD cells[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IMC-EB10 Related Antibodies

Western Blot Analysis[1]

Cell Line: Hb1119, SEM-K2 cells
Concentration: 10 μg/mL
Incubation Time: 1 h
Result: Reduced FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK.

Western Blot Analysis[1]

Cell Line: REH, RS411 cells
Concentration: 10 μg/mL
Incubation Time: 1 h
Result: Activated FLT3 and phosphorylation of downstream signaling proteins STAT5, Akt, and MAPK.

Western Blot Analysis[1]

Cell Line: ALLs
Concentration: 10 μg/mL
Incubation Time: 1 h
Result: Activated FLT3 and downstream Akt.

ELISA Assay[4]

Cell Line: EOL-1, EM3, BaF3-ITD, MV4;11 cells
Concentration: 0.1, 0.4, 1, 4, 10, 40, 100, 200 nM
Incubation Time: 1 h
Result: Blocked FL-induced FLT3 receptor phosphorylation in a dose dependent manner with an IC50 of 0.4 to 4 nM.
Blocked the phosphorylation and constitutive phosphorylation of MAPK, inhibited FL-induced phosphorylation of AKT and Stat5 phosphorylation in EOL-1 and BaF3-ITD cells.
In Vivo

IMC-EB10 (400 μg/10 mg/kg, i.p., thrice per week starting 24 hours after cell injection/once starting 24 hours after cell injection/a total of thrice every other day starting 24 hours after cell injection or thrice per week starting 7 days after cell injection, 30 days/2×/week, 3 weeks) reduces the presence of SEM-K2 cells, mediates cytotoxicity through natural killer cells, does not select for resistant cells, prolongs survival compared to Methotrexate (HY-14519) alone in SEM-K2 NOD/SCID mice model[1][3].
IMC-EB10 (400 μg, i.p., three times a week, 14 weeks) reduces cell implantation in ALLs NOD/SCID mice model[1].
IMC-EB10 (100-500 μg, i.p., 3 times weekly, 20 days) decreases the number of tumor cells in bone marrow and prolongs the survival in EOL-1 and BaF3-ITD xenograft leukemia model[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SEM-K2 (0.5×106) NOD/SCID mice model[1]
Dosage: 400 μg
Administration: i.p., thrice per week starting 24 hours after cell injection/once starting 24 hours after cell injection/a total of thrice every other day starting 24 hours after cell injection or thrice per week starting 7 days after cell injection, 30 days
Result: Reduced human cells in peripheral blood, spleen, and bone marrow, reducing the presence of SEM-K2 cells to <1%, prolonged survival. Did not select for resistant cells, mediated cytotoxicity through natural killer cells.
Animal Model: ALLs (1×106) NOD/SCID mice model[1]
Dosage: 400 μg
Administration: i.p., three times a week, 14 weeks
Result: Reduced cell implantation.
Animal Model: SEM-K2 (5×105) NOD/SCID mice model[3]
Dosage: 10 mg/kg + 100 mg/kg Methotrexate
Administration: i.p., 2×/week, 3 weeks + once per week for 3 weeks
Result: Significantly prolonged survival compared to Methotrexate alone.
Animal Model: EOL-1 (5×106) xenograft leukemia NOD/SCID mice (male, , 6-8 weeks) model[4]
Dosage: 100, 250, 500 μg
Administration: i.p., 3 times weekly, 20 days
Result: Decreased the number of tumor cells in bone marrow.
Animal Model: BaF3-ITD (5×104) xenograft leukemia NOD/SCID mice (male, , 6-8 weeks) model[4]
Dosage: 100, 500 μg
Administration: i.p., 3 times weekly
Result: Prolonged the survival.
Gene ID

2322  [NCBI]

Accession
Target

FLT3
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
SMILES

N/A
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

IMC-EB10 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

IMC-EB10LY3012218LY 3012218LY-3012218FLT3p38 MAPKSTATPI3KAktCluster of differentiation antigen 135CD135Fms like tyrosine kinase 3Phosphoinositide 3-kinasePKBProtein kinase BAntibodyleukemiaHb1119 cellsSEM-K2 cellsEOL-1 cellsEM3 cellsBaF3-ITD cellsMV4;11 cellsleukemia NOD/SCID miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
IMC-EB10
Cat. No.:
HY-P991641
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.